tirzepatide long-acting injectable (IVL3024) / Inventage Lab - LARVOL DELTA

Inventage Lab presents ADA data on long-acting semaglutide, tirzepatide obesity therapies (Korea Biomedical Review) - "IVL3021, a once-monthly semaglutide-based LAI candidate, demonstrated dose-dependent weight loss in a diet-induced obesity (DIO) rat model...The treatment maintained its weight-reduction effect with only one injection per month and demonstrated weight-loss efficacy comparable to that of repeated once-weekly dosing with Wegovy...Body composition analysis and histopathological assessments also revealed significant reductions in fat mass in the IVL3021-treated group, along with a trend toward smaller adipocyte size....In a minipig model, a single subcutaneous injection of IVL3024 achieved sustained and stable drug exposure without an initial burst release over a two-month evaluation period....'We are preparing to advance the clinical development of IVL3021, our long-acting semaglutide injectable, within this year.'"

Preclinical • Obesity